Organisation paid for research Program year 2025 Source: CMS Open Payments

Eastside Therapeutic Resource Inc

Neither a doctor nor a teaching hospital

Research payments

$8,108,116

608 payments

Through program year 2025, Eastside Therapeutic Resource Inc is reported as receiving $8,108,116 in research payments, across 608 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $1,460,854 214
2024 Research $740,116 66
2023 Research $838,241 32
2022 Research $1,027,564 36
2021 Research $1,343,767 67
2020 Research $1,619,836 122
2019 Research $1,077,740 71

Breakdown

Who paid Research payments · program years 2019–2025
  1. Otsuka Pharmaceutical Development & Commercialization, Inc. $2,430,171 32 payments
  2. AbbVie, Inc. $1,363,428 152 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $1,122,615 31 payments
  4. Allergan Inc. $1,038,101 117 payments
  5. F. Hoffmann-La Roche AG $840,898 43 payments
  6. Janssen Research & Development, LLC $339,569 19 payments
  7. ITI, Inc. $239,056 97 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $127,030 12 payments
  9. Genentech, Inc. $98,650 8 payments
  10. Biogen, Inc. $96,483 5 payments
Studies the money was for Research payments · program years 2019–2025
  1. V1a 2 in Pediatric Autism $840,898 43 payments
  2. A Phase 3, Multicenter, Randomized, Double-Blind Trial of Fixed-Dose Brexpiprazole As Combination Therapy With Sertraline in the Treatment of Adults With Post-Traumatic Stress Disorder $549,982 3 payments
  3. A Multicenter, Randomized, Flexible-Dose, Double Blind Trial of Brexpiprazole Versus Placebo for the Treatment of Adults With Borderline Personality Disorder $510,561 2 payments
  4. Proof of concept and DRF in BPD $500,879 3 payments
  5. A Double-Blind, Placebo-Controlled Study of Cariprazine As Adjunctive Therapy in Major Depressive Disorder $476,491 34 payments
  6. Open-Label Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia or Bipolar I Disorder $375,768 17 payments
  7. A Double-Blind, Placebo-Controlled Study of Cariprazine As Adjunctive Therapy in Major Depressive Disorder $288,360 24 payments
  8. A Phase 3, Multicenter, Randomized, Double-Blind Trial of Fixed-Dose Brexpiprazole As Combination Therapy With Sertraline in the Treatment of Adults With Post-Traumatic Stress Disorder $287,029 2 payments
  9. A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder $277,162 16 payments
  10. A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso $227,338 12 payments
What the money was spent on Research payments · program years 2019–2025
  1. Other $120,608 10 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record